Epsilogen: Funding, Investors & Team (Oct 2026)
IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor.
Epsilogen has raised $57.6M across 2 funding rounds on record, the most recent a Series B of $16.4M announced in Sep 2024.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Epsilogen Company Profile and Key Stats
Latest funding round on record: Sep 2024.
Epsilogen Funding Rounds
Epsilogen raised $41.2M in a Series B announced in Mar 2022.
2.5 years later, a Series B of $16.4M was announced in Sep 2024.
Epsilogen Founders and Leadership Team
Contact details for the Epsilogen team: 1 of 2 have an email address on file.
Start 14-day free trial →Epsilogen Funding Compared to Other Biotechnology Startups
Epsilogen's latest round of $16.4M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Epsilogen in Biotechnology and London
Companies Similar to Epsilogen
Microbiotica develops treatments involving live bacteria found in the human microbiome, aiming to identify…
OMass Technologies is a drug discovery company exploiting novel mass spectrometry platforms to develop…
HydRegen, based in Oxford, UK, is a biotech firm that offers eco-friendly alternatives for the production of…
R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug…
The perfect package for any general surgical trainee or resident. Progress from beginner to advanced surgical…
Argonaute RNA company research projects build on existing intellectual property.
An innovative C elegans company that serves the biotech, nutrition, and other industries and fields of study…
ViaNautis, previously known as SomaServe, was established in 2018 as a separate entity from UCL under the…
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
Epsilogen Funding FAQs
What does Epsilogen do?
IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor.
How much funding has Epsilogen raised?
Epsilogen has raised $57.6M across 2 rounds on record. The most recent is a Series B of $16.4M announced in Sep 2024.
When did Epsilogen last raise funding?
Epsilogen's most recent funding round on record is a Series B of $16.4M, announced in Sep 2024.
Who founded Epsilogen?
FundedIQ lists Sophia Karagiannis (Founder) at Epsilogen.
Who is the CEO of Epsilogen?
Tim Wilson is listed as CEO at Epsilogen.
Where is Epsilogen headquartered?
Epsilogen is based in London, England, United Kingdom.
How many employees does Epsilogen have?
Epsilogen is in the 11-50 employee band.
How does Epsilogen's funding compare to other Biotechnology startups?
Epsilogen's latest round of $16.4M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Epsilogen Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Epsilogen is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.